Your browser doesn't support javascript.
loading
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Du, Ting; Song, Yan; Ray, Arghya; Wan, Xueping; Yao, Yao; Samur, Mehmet K; Shen, Chen; Penailillo, Johany; Sewastianik, Tomasz; Tai, Yu-Tzu; Fulciniti, Mariateresa; Munshi, Nikhil C; Wu, Hao; Carrasco, Ruben D; Chauhan, Dharminder; Anderson, Kenneth C.
Afiliación
  • Du T; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Song Y; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Ray A; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Wan X; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Yao Y; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Samur MK; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Shen C; Department of Biostatistics and Computational Biology, Harvard T.H. Chan School of Public Health, Harvard Medical School, Harvard University, Boston, MA.
  • Penailillo J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, MA.
  • Sewastianik T; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA.
  • Tai YT; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Fulciniti M; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Munshi NC; Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Wu H; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Carrasco RD; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Chauhan D; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA.
  • Anderson KC; VA Boston Healthcare System, Boston, MA.
Blood ; 141(21): 2599-2614, 2023 05 25.
Article en En | MEDLINE | ID: mdl-36630605
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complejo de la Endopetidasa Proteasomal / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Marruecos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Complejo de la Endopetidasa Proteasomal / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Marruecos